Ra Pharmaceuticals launches late-stage zilucoplan trial for gMG

Ra Pharmaceuticals (NASDAQ:RARX) initiates dosing in the RAISE study, its pivotal, Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG).

The trial is expected to enroll approx. 130 patients.

The primary endpoint is the change in the MG Activities of Daily Living (MG-ADL) score from baseline to week 12. Top-line results are expected in early 2021.

https://seekingalpha.com/news/3503286-ra-pharmaceuticals-launches-late-stage-zilucoplan-trial-gmg